Opus Genetics Receives 'Moderate Buy' Rating from Analysts

Eleven analysts cover the company, with one sell, nine buy, and one strong buy recommendations.

Apr. 9, 2026 at 8:18am

Got story updates? Submit your updates here. ›

An extreme close-up of a series of gears, levers, and metal components that make up the inner workings of a banking machine, conveying the idea of the heavy, tangible mechanics that underpin the financial system.The complex financial infrastructure that powers the stock market and banking industry is the unseen foundation for corporate success and individual wealth.Farmington Hills Today

Shares of Opus Genetics, Inc. (NASDAQ:IRD) have received a consensus recommendation of 'Moderate Buy' from the eleven analysts currently covering the company, according to Marketbeat. The average 12-month price target among the analysts is $10.11.

Why it matters

Opus Genetics is a clinical-stage ophthalmic biopharmaceutical company focused on developing therapies for refractive and retinal eye disorders. The 'Moderate Buy' rating from analysts suggests they see potential upside in the company's stock, which could signal confidence in its pipeline and future growth prospects.

The details

The analyst coverage breakdown includes one sell recommendation, nine buy recommendations, and one strong buy recommendation. Several firms have issued reports on the stock, with BTIG Research increasing their target price from $7 to $12 and giving the stock a 'buy' rating, while B. Riley Financial and Cantor Fitzgerald have also initiated coverage with buy ratings and price targets of $9 and $15, respectively.

  • Opus Genetics stock opened at $5.15 on Thursday, April 9, 2026.
  • The stock has a 12-month low of $0.65 and a 12-month high of $5.30.

The players

Opus Genetics, Inc.

A clinical-stage ophthalmic biopharmaceutical company focused on developing therapies for refractive and retinal eye disorders.

BTIG Research

An equity research firm that covers Opus Genetics and increased their target price to $12 with a 'buy' rating.

B. Riley Financial

An investment bank that initiated coverage of Opus Genetics with a 'buy' rating and $9 price target.

Cantor Fitzgerald

An investment bank that initiated coverage of Opus Genetics with an 'overweight' rating and $15 price target.

Got photos? Submit your photos here. ›

What they’re saying

“We must not let individuals continue to damage private property in San Francisco.”

— Robert Jenkins, San Francisco resident

“Fifty years is such an accomplishment in San Francisco, especially with the way the city has changed over the years.”

— Gordon Edgar, Grocery employee

The takeaway

The 'Moderate Buy' rating from analysts on Opus Genetics' stock suggests the company's pipeline and growth potential are viewed favorably, despite the competitive landscape for ophthalmic therapies. Investors will likely watch for further updates on the company's clinical development programs and any potential regulatory milestones.